Kailera Therapeutics Files Initial Ownership Statement
Ticker: KLRA · Form: 3 · Filed: Apr 16, 2026
Sentiment: neutral
Topics: insider-filing, ownership, regulatory
TL;DR
Kailera Therapeutics (KR) filed a Form 3 on 4/16/26 - initial ownership report.
AI Summary
On April 16, 2026, Kailera Therapeutics, Inc. (CIK: 0002096997) filed a Form 3, an initial statement of beneficial ownership of securities. The filing was made by Paul D. Burgess, who is listed as the reporting person with CIK 0001744627. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates the initial reporting of beneficial ownership for securities related to Kailera Therapeutics, Inc., which is a crucial step in regulatory compliance for new or significantly changing ownership structures.
Risk Assessment
Risk Level: low — A Form 3 filing is a standard regulatory requirement and does not inherently indicate financial risk.
Key Players & Entities
- Kailera Therapeutics, Inc. (company) — Issuer
- 0002096997 (company) — Kailera Therapeutics, Inc. CIK
- Paul D. Burgess (person) — Reporting Person
- 0001744627 (person) — Paul D. Burgess CIK
- 2026-04-16 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a Form 3, an initial statement of beneficial ownership of securities.
Who is the reporting person in this filing?
The reporting person is Paul D. Burgess (CIK: 0001744627).
What is the CIK for Kailera Therapeutics, Inc.?
The CIK for Kailera Therapeutics, Inc. is 0002096997.
When was this filing accepted by the SEC?
The filing was accepted on April 16, 2026.
What is the business address of Kailera Therapeutics, Inc.?
The business address is 180 THIRD AVENUE, 4TH FLOOR, WALTHAM MA 02451.
Filing Details
This Initial Statement of Beneficial Ownership (Form 3) was filed with the SEC on April 16, 2026 by Paul D. Burgess regarding Kailera Therapeutics, Inc. (KLRA). Form 3 filings establish the initial ownership position of company insiders when they first assume their role.